



## **Exelixis Announces June 25 Webcast of Presentation at the Piper Jaffray Europe Conference**

June 18, 2008

SOUTH SAN FRANCISCO, Calif., June 18, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that Frank Karbe, executive vice president and chief financial officer at Exelixis, will present at the Piper Jaffray Europe Conference at 3:40 a.m. PT/6:40 a.m. ET/11:40 a.m. London, UK time on Wednesday, June 25, 2008. Mr. Karbe will discuss updates to the company's development pipeline and corporate strategy.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at <http://www.exelixis.com>.

### About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's website at <http://www.exelixis.com>.

SOURCE Exelixis, Inc.

<http://www.exelixis.com>